Custom antibody development

We offer world-leading antibody development platforms based on a proprietary RabMAb® rabbit monoclonal platform, a phase display platform (AxioMx), and a next-generation sequencing platform (NGS-RabMAb®)

Region I is sufficient for binding TP53 and inhibiting its G1 arrest and apoptosis functions. It also binds TP73. Region II contains most of a central acidic region and a putative C4-type zinc finger. The RING finger domain which coordinates two molecules of zinc mediates the heterooligomerization with MDM2.

If we know of our antibodies being used in any references/publications, we will list these under the "Specific References" section of our datasheet, which can be found under the shipping and pricing...